BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Phase 1

Completed

Conditions: Hemophilia A

Interventions: Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)

First Posted Date: 2010-08-19

Last Posted Date: 2018-09-07

Lead Sponsor: Bayer

Target Recruit Count: 14

Registration Number: NCT01184820

Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.

Phase 2

Completed

Conditions: Pulmonary Hypertension

Interventions: Drug: Riociguat (Adempas, BAY63-2521)
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2010-08-11

Last Posted Date: 2016-08-29

Lead Sponsor: Bayer

Target Recruit Count: 18

Registration Number: NCT01179334

Locations: 🇬🇧
Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom
🇨🇿
Vseobecna fakultni nemocnice, Praha 2, Czech Republic

Japanese BAY86-9766 Monotherapy Phase I Study

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BAY86-9766

First Posted Date: 2010-08-11

Last Posted Date: 2017-06-20

Lead Sponsor: Bayer

Target Recruit Count: 12

Registration Number: NCT01179295

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

Phase 2

Terminated

Conditions: Ventricular Dysfunction, Left
Hypertension, Pulmonary

Interventions: Drug: Riociguat (BAY63-2521)
Drug: Placebo

First Posted Date: 2010-07-30

Last Posted Date: 2014-11-04

Lead Sponsor: Bayer

Target Recruit Count: 39

Registration Number: NCT01172756

Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder

Phase 1

Completed

Conditions: Infection
Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Cipro Inhale (Ciprofloxacin, BAYQ3939)

First Posted Date: 2010-07-23

Last Posted Date: 2014-04-14

Lead Sponsor: Bayer

Target Recruit Count: 12

Registration Number: NCT01168895

Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors

Phase 2

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: BAY60-4552 plus Vardenafil
Drug: Placebo
Drug: Vardenafil

First Posted Date: 2010-07-23

Last Posted Date: 2014-11-04

Lead Sponsor: Bayer

Target Recruit Count: 140

Registration Number: NCT01168817

Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Acarbose (Glucobay, BAYG5421)

First Posted Date: 2010-07-22

Last Posted Date: 2010-08-25

Lead Sponsor: Bayer

Target Recruit Count: 3310

Registration Number: NCT01167231

Coronary Vasomotor Response After Riociguat Exposure

Phase 2

Withdrawn

Conditions: Coronary Artery Disease

Interventions: Drug: Riociguat (BAY63-2521)

First Posted Date: 2010-07-20

Last Posted Date: 2013-10-23

Lead Sponsor: Bayer

Registration Number: NCT01165931

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Completed

Conditions: Lymphoma, Follicular
Non-Hodgkin Lymphoma

Interventions: Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

First Posted Date: 2010-07-19

Last Posted Date: 2010-08-24

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT01164696

A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment

Phase 3

Completed

Conditions: Age-Related Memory Disorders

Interventions: Dietary Supplement: Multivitamin/Multimineral/Ginkgo (BAY 81-2775)
Other: Placebo

First Posted Date: 2010-07-12

Last Posted Date: 2010-08-02

Lead Sponsor: Bayer

Target Recruit Count: 132

Registration Number: NCT01160692

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy